当前位置: 首页 >> 检索结果
401. The effect of adherence to practice guidelines on depression outcomes.
作者: Kimberly A Hepner.;Melissa Rowe.;Kathryn Rost.;Scot C Hickey.;Cathy D Sherbourne.;Daniel E Ford.;Lisa S Meredith.;Lisa V Rubenstein.
来源: Ann Intern Med. 2007年147卷5期320-9页
Few studies have assessed clinician adherence to depression practice guidelines and the relationship between clinician adherence and depression outcomes.
402. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
作者: Peter M Okin.;Richard B Devereux.;Katherine E Harris.;Sverker Jern.;Sverre E Kjeldsen.;Stevo Julius.;Jonathan M Edelman.;Björn Dahlöf.; .
来源: Ann Intern Med. 2007年147卷5期311-9页
Reduction of electrocardiographic left ventricular hypertrophy (LVH) has been associated with decreased cardiovascular death, stroke, myocardial infarction, and atrial fibrillation. However, whether reduction of electrocardiographic LVH is associated with decreased heart failure is unclear.
403. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
作者: Keith A A Fox.;Jean-Pierre Bassand.;Shamir R Mehta.;Lars Wallentin.;Pierre Theroux.;Leopoldo Soares Piegas.;Vicent Valentin.;Tiziano Moccetti.;Susan Chrolavicius.;Rizwan Afzal.;Salim Yusuf.; .
来源: Ann Intern Med. 2007年147卷5期304-10页
A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS). Renal dysfunction increases the risk for major bleeding.
404. Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients: a randomized trial.
作者: Jakob Stensballe.;Michael Tvede.;Dagnia Looms.;Freddy Knudsen Lippert.;Benny Dahl.;Else Tønnesen.;Lars Simon Rasmussen.
来源: Ann Intern Med. 2007年147卷5期285-93页
Urinary tract infection is one of the most common nosocomial infections in hospitalized patients. It is predominantly associated with indwelling urinary catheters.
405. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial.
作者: Saverio Stranges.;James R Marshall.;Raj Natarajan.;Richard P Donahue.;Maurizio Trevisan.;Gerald F Combs.;Francesco P Cappuccio.;Antonio Ceriello.;Mary E Reid.
来源: Ann Intern Med. 2007年147卷4期217-23页
Findings from animal models suggest that selenium supplementation improves glucose metabolism.
406. Cystatin C as a risk factor for outcomes in chronic kidney disease.
作者: Vandana Menon.;Michael G Shlipak.;Xuelei Wang.;Josef Coresh.;Tom Greene.;Lesley Stevens.;John W Kusek.;Gerald J Beck.;Allan J Collins.;Andrew S Levey.;Mark J Sarnak.
来源: Ann Intern Med. 2007年147卷1期19-27页
No study has compared cystatin C level, serum creatinine concentration, and estimated glomerular filtration rate (GFR) as risk factors for outcomes in chronic kidney disease (CKD), and none has compared measured GFR with CKD in any population.
407. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.
作者: Nanette K Wenger.;Sandra J Lewis.;David M Herrington.;Vera Bittner.;Francine K Welty.; .
来源: Ann Intern Med. 2007年147卷1期1-9页
Increased life expectancy is associated with an increase in the burden of chronic cardiovascular disease.
408. Different ways to describe the benefits of risk-reducing treatments: a randomized trial.
作者: Peder A Halvorsen.;Randi Selmer.;Ivar Sønbø Kristiansen.
来源: Ann Intern Med. 2007年146卷12期848-56页
How physicians communicate the risks and benefits of medical care may influence patients' choices. Ways to communicate the benefits of risk-reducing drug therapies include the number needed to treat (NNT) to prevent adverse events, such as heart attacks or hip fractures, and gains in disease-free life expectancy or postponement of adverse events. Previous studies suggest that the magnitude of the NNT does not affect a layperson's decision about risk-reducing interventions, but postponement of an adverse event does affect such decisions.
409. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial.
作者: Herbert Marini.;Letteria Minutoli.;Francesca Polito.;Alessandra Bitto.;Domenica Altavilla.;Marco Atteritano.;Agostino Gaudio.;Susanna Mazzaferro.;Alessia Frisina.;Nicola Frisina.;Carla Lubrano.;Michele Bonaiuto.;Rosario D'Anna.;Maria Letizia Cannata.;Francesco Corrado.;Elena Bianca Adamo.;Steven Wilson.;Francesco Squadrito.
来源: Ann Intern Med. 2007年146卷12期839-47页
Observational studies and small trials of short duration suggest that the isoflavone phytoestrogen genistein reduces bone loss, but the evidence is not definitive.
410. Physiotherapist-directed exercise, advice, or both for subacute low back pain: a randomized trial.
作者: Liset H M Pengel.;Kathryn M Refshauge.;Christopher G Maher.;Michael K Nicholas.;Robert D Herbert.;Peter McNair.
来源: Ann Intern Med. 2007年146卷11期787-96页
Advice and exercise are widely recommended for subacute low back pain, but the effectiveness of these interventions is unclear.
411. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.
作者: Michael D Murray.;James Young.;Shawn Hoke.;Wanzhu Tu.;Michael Weiner.;Daniel Morrow.;Kevin T Stroupe.;Jingwei Wu.;Daniel Clark.;Faye Smith.;Irmina Gradus-Pizlo.;Morris Weinberger.;D Craig Brater.
来源: Ann Intern Med. 2007年146卷10期714-25页
Patients with heart failure who take several prescription medications sometimes have poor adherence to their treatment regimens. Few interventions designed to improve adherence to therapy have been rigorously tested.
412. A sustained mortality benefit from screening for abdominal aortic aneurysm.
作者: Lois G Kim.;R Alan P Scott.;Hilary A Ashton.;Simon G Thompson.; .
来源: Ann Intern Med. 2007年146卷10期699-706页
Longer-term mortality benefit and cost-effectiveness for abdominal aortic aneurysm (AAA) screening are uncertain.
413. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial.
作者: Joseph J Gallo.;Hillary R Bogner.;Knashawn H Morales.;Edward P Post.;Julia Y Lin.;Martha L Bruce.
来源: Ann Intern Med. 2007年146卷10期689-98页
Few studies have tested the effects of a depression intervention on the risk for death associated with depression.
414. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
作者: Carlo Salvarani.;PierLuigi Macchioni.;Carlo Manzini.;Giuseppe Paolazzi.;Aldo Trotta.;Paolo Manganelli.;Marco Cimmino.;Roberto Gerli.;Maria Grazia Catanoso.;Luigi Boiardi.;Fabrizio Cantini.;Catherine Klersy.;Gene G Hunder.
来源: Ann Intern Med. 2007年146卷9期631-9页
A reliable alternative to steroids for treating polymyalgia rheumatica has not yet been identified. Although infliximab has been used occasionally in steroid-resistant cases, its efficacy has not been demonstrated in a controlled study.
415. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
作者: Gary S Hoffman.;Maria C Cid.;Karen E Rendt-Zagar.;Peter A Merkel.;Cornelia M Weyand.;John H Stone.;Carlo Salvarani.;Weichun Xu.;Sudha Visvanathan.;Mahboob U Rahman.; .
来源: Ann Intern Med. 2007年146卷9期621-30页
Tumor necrosis factor-alpha is present in arteries in giant cell arteritis.
416. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
作者: William J Sandborn.;Paul Rutgeerts.;Robert Enns.;Stephen B Hanauer.;Jean-Frédéric Colombel.;Remo Panaccione.;Geert D'Haens.;Ju Li.;Marie R Rosenfeld.;Jeffrey D Kent.;Paul F Pollack.
来源: Ann Intern Med. 2007年146卷12期829-38页
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent.
417. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.
作者: Joel G Ray.;Clive Kearon.;Qilong Yi.;Patrick Sheridan.;Eva Lonn.; .
来源: Ann Intern Med. 2007年146卷11期761-7页
Elevated total homocysteine levels are associated with a higher risk for venous thromboembolism. Whether decreasing homocysteine levels with vitamin therapy reduces the risk for venous thromboembolism is not known.
418. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.
作者: Dino Vaira.;Angelo Zullo.;Nimish Vakil.;Luigi Gatta.;Chiara Ricci.;Federico Perna.;Cesare Hassan.;Veronica Bernabucci.;Andrea Tampieri.;Sergio Morini.
来源: Ann Intern Med. 2007年146卷8期556-63页
Antimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide.
419. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
作者: Bernard Zinman.;Byron J Hoogwerf.;Santiago Durán García.;Denái R Milton.;Joseph M Giaconia.;Dennis D Kim.;Michael E Trautmann.;Robert G Brodows.
来源: Ann Intern Med. 2007年146卷7期477-85页
Exenatide therapy is effective in combination with metformin or sulfonylureas for treating type 2 diabetes. Thiazolidinediones (TZDs) also are commonly used, but the efficacy of exenatide with a TZD has not been reported.
420. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
作者: Susan L Greenspan.;Joel B Nelson.;Donald L Trump.;Neil M Resnick.
来源: Ann Intern Med. 2007年146卷6期416-24页
Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures.
|